Drugs / Black Seed Oil
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06542887 | Oct 2024 → Oct 2025 overdue | attention deficit-hyperactivity disorder | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03959306 | Apr → Aug 2019 | type 2 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05957432 Comparator | Aug 2023 → Oct 2025 overdue | Helicobacter pylori infectious disease | Ain Shams University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | black seed oil | “Dietary Supplement: Black Seed Oil” NCT03959306 ↗ |
| Known as | BSO | “Black seed oil (BSO) has shown anti-inflammatory and antioxidant properties in several human studies.” NCT06542887 ↗ |
| Route | Oral | “black seed oil in the form of soft gelatin capsule 450 mg” NCT06542887 ↗ |